Direct evidence of constitutive PI3K activation in AML was initially described in 2004, when expression of the p85α subunit of PI3K was detected in nearly all AML samples and of 40 AML patients, 21 cases exhibited increased PI3K activity. Here, PIK3CA is linked to acute myeloid leukemia.